EPITHELIAL OVARIAN CANCER

This study looked at how well the drug niraparib works and its safety in 850 Korean women with ovarian cancer. It included patients who received niraparib as maintenance therapy after initial treatment or as a later treatment. The researchers measured how long patients lived with…

This early-phase study tested a combination of two experimental drugs (vobramitamab duocarmazine and lorigerlimab) in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…

This study tested a new drug called RC88 in 43 women with ovarian, fallopian tube, or peritoneal cancer that stopped responding to platinum chemotherapy. The goal was to see if RC88 could shrink tumors and how safe it was. Participants had already tried at least three other treat…

This study tested a new drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, or breast cancer) that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was completed, but res…

This early-stage trial tested a new drug called SL-172154 combined with either standard chemotherapy or a targeted therapy in 86 people with ovarian cancer that stopped responding to platinum-based chemo. The main goals were to check safety and find the best dose. Researchers als…

This study looked for DNA markers in blood that could help detect a serious type of ovarian cancer early. Researchers compared blood and tissue samples from 10 women with and without the disease. The goal is to develop a simple blood test for earlier diagnosis.

This study looked at 1,500 women with advanced ovarian, peritoneal, or fallopian tube cancer to see how genetic changes in their tumors relate to how long they live without the disease getting worse. Researchers collected tumor samples and medical information to build a database …

This study looked back at the medical records of 51 people with ovarian, fallopian tube, or peritoneal cancer who took the drug rucaparib. The goal was to see how well the drug works and how safe it is in real-world patients, not just in strict clinical trials. Researchers collec…

This study aimed to create a blood test that could predict when ovarian, peritoneal, or fallopian tube cancer might come back after remission. Researchers looked at proteins in the blood to find a pattern, or 'fingerprint,' linked to relapse. 119 women with stage III or IV cancer…